0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Cardiovascular medicine

Buy Now

Razoxane and Dexrazoxane - Two Multifunctional Agents - Experimental and Clinical Results (Paperback, 2011 ed.) Loot Price: R4,218
Discovery Miles 42 180
Razoxane and Dexrazoxane - Two Multifunctional Agents - Experimental and Clinical Results (Paperback, 2011 ed.): Walter...

Razoxane and Dexrazoxane - Two Multifunctional Agents - Experimental and Clinical Results (Paperback, 2011 ed.)

Walter Rhomberg, Kurt Hellmann

 (sign in to rate)
Loot Price R4,218 Discovery Miles 42 180 | Repayment Terms: R395 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Donate to Against Period Poverty

Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimers disease could be stabilized by one or both these drugs.

General

Imprint: Springer
Country of origin: Netherlands
Release date: November 2014
First published: 2011
Editors: Walter Rhomberg • Kurt Hellmann
Dimensions: 235 x 155 x 14mm (L x W x T)
Format: Paperback
Pages: 243
Edition: 2011 ed.
ISBN-13: 978-9401780483
Categories: Books > Medicine > Clinical & internal medicine > Cardiovascular medicine
Books > Science & Mathematics > Biology, life sciences > Life sciences: general issues > Neurosciences
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > Radiotherapy
LSN: 940178048X
Barcode: 9789401780483

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners